Complex and Customized: Manufacturing New Molecular Formats
Increasingly complex monoclonal antibody molecules will require the right “tool box” for scaling up manufacturing.
Now that high yields have been achieved for the first generation of monoclonal antibodies, the next challenge will be developing ways to produce larger quantities of even more complex antibody formats. These increasingly complex molecules will require the right “tool box” for scaling up manufacturing.
Read this article in BioPharm International's Outsourcing Resources 2019 eBook.
Article Details
BioPharm International
eBook: Outsourcing Resources 2019
April 2019
Pages: 16–19
Citation
When referring to this article, please cite it as Andy Racher, "Complex and Customized: Manufacturing New Molecular Formats,"BioPharm International's Outsourcing Resources eBook (April 2019).
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
